Skytrofa
Active substance: lonapegsomatropin
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · LONAPEGSOMATROPIN 13.3 mg/1
United StatesActive
Marketing holder: Ascendis Pharma Endocrinology, Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- LONAPEGSOMATROPIN · 13.3 mg/1
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1208c-d080-79c3-8a8f-e604ba7d628b,01a1208d-bfc8-728d-b89c-6970fd819fc6,01a12090-f05f-7479-b719-d4b99f039f94,01a12092-ba4a-7b72-b60d-57f9f7ac3903,01a12092-ba4f-7335-a4b4-7d523d7f9fa4;count=14 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 73362-011
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- SUBCUTANEOUS
Sources
- product · openFDA NDC · 73362-011 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 73362-011 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 73362-011 · Verified 2026-10-09 · open in source